Compare Amphastar Pharmaceuticals Inc (AMPH) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Nasdaq Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Nasdaq Inc trades at $95.01 (market cap $53.45B). The key difference: Nasdaq Inc is far larger — about 61.9× Amphastar Pharmaceuticals Inc's market cap, and Nasdaq Inc pays a 1.21% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | NDAQ | |
|---|---|---|
Market Cap | $863.95M | $53.45B |
Sector | Health | Financials |
52-Week High | $30.81 | $100.98 |
52-Week Low | $16.87 | $76.85 |
Enterprise Value | $1.26B | $59.91B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Nasdaq (NDAQ) trades at $94.59, down slightly by 0.12% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.07 per share, beating estimates, and maintains robust profitability with a 22.52% net income margin. Recent news highlights steady exchange operations and strategic growth initiatives.
Outlook remains positive with a consensus price target of $109.20, implying 15% upside. Risks include market volatility and competitive pressures, but solid fundamentals and analyst buy ratings support a favorable investment case for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
